| Kelly Lang-sheppard, APRN-CNS | |
|
5401 N Portland Ave Ste 410, Oklahoma City, OK 73112-2131 | |
| (405) 945-4700 | |
| (405) 945-4270 |
| Full Name | Kelly Lang-sheppard |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 13 Years |
| Location | 5401 N Portland Ave Ste 410, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972940708 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 60786 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integris Ambulatory Care Corporation | 2365408465 | 382 |
News Archive
The Washington Post: Supreme Court nominee Elena Kagan suggested at her confirmation hearing Tuesday "that a controversial requirement in the new federal health-care law that most Americans obtain insurance has a legal basis - a question that is likely to come before the courts." In answering Republican senators, Kagan "signaled" that she supported "enacting a health-care law that for the first time will require most legal residents of the United States to obtain insurance.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.
Increased incidence of gastroesophageal reflux symptoms (GERS) reported by a large population of 9/11 World Trade Center attack survivors, most of whom had not reported any GERD-related symptoms prior to 9/11, worsened the health-related quality life for many rescue and recovery workers, lower-Manhattan residents and local workers who were exposed to the dust cloud and other contaminants in the aftermath of 9/11, according to a study published online today online today in The American Journal of Gastroenterology.
DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.
› Verified 8 days ago
| Entity Name | Integris Ambulatory Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
The Washington Post: Supreme Court nominee Elena Kagan suggested at her confirmation hearing Tuesday "that a controversial requirement in the new federal health-care law that most Americans obtain insurance has a legal basis - a question that is likely to come before the courts." In answering Republican senators, Kagan "signaled" that she supported "enacting a health-care law that for the first time will require most legal residents of the United States to obtain insurance.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.
Increased incidence of gastroesophageal reflux symptoms (GERS) reported by a large population of 9/11 World Trade Center attack survivors, most of whom had not reported any GERD-related symptoms prior to 9/11, worsened the health-related quality life for many rescue and recovery workers, lower-Manhattan residents and local workers who were exposed to the dust cloud and other contaminants in the aftermath of 9/11, according to a study published online today online today in The American Journal of Gastroenterology.
DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Lang-sheppard, APRN-CNS 5300 N Independence Ave, Suite 280, Oklahoma City, OK 73112-5556 Ph: (405) 945-4700 | Kelly Lang-sheppard, APRN-CNS 5401 N Portland Ave Ste 410, Oklahoma City, OK 73112-2131 Ph: (405) 945-4700 |
News Archive
The Washington Post: Supreme Court nominee Elena Kagan suggested at her confirmation hearing Tuesday "that a controversial requirement in the new federal health-care law that most Americans obtain insurance has a legal basis - a question that is likely to come before the courts." In answering Republican senators, Kagan "signaled" that she supported "enacting a health-care law that for the first time will require most legal residents of the United States to obtain insurance.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.
Increased incidence of gastroesophageal reflux symptoms (GERS) reported by a large population of 9/11 World Trade Center attack survivors, most of whom had not reported any GERD-related symptoms prior to 9/11, worsened the health-related quality life for many rescue and recovery workers, lower-Manhattan residents and local workers who were exposed to the dust cloud and other contaminants in the aftermath of 9/11, according to a study published online today online today in The American Journal of Gastroenterology.
DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.
› Verified 8 days ago
Jamie Louise Hunt, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young, Andrews Academic Tower, Suite 8400, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 405-271-5892 | |
Mrs. Janet Elizabeth Kristic, APRN CLINICAL NURSE Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1117 Nw 50th, Oklahoma City, OK 73118 Phone: 405-842-4435 Fax: 405-842-2846 | |
Todd J Ramer, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4300 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-752-3539 | |
Andrea Jeanne Mccoy, R.N. Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4050 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-608-3800 Fax: 405-608-3838 | |
Shanelle Stensaas, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-613-3351 | |
Leighann Fullagar, APRN-CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-713-7403 Fax: 405-713-2794 | |
Michelle Tull, ACNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 800 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-3402 |